<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Immunosuppressants: rheumatic disease; Gold; Penicillamine: rheumatic disease; Hydroxychloroquine; Chloroquine: rheumatic disease; Sulfasalazine: rheumatic disease; Arthritis: psoriatic; Disease-modifying antirheumatic drugs; Rheumatism, palindromic; Lupus erythematosus: systemic; Lupus erythematosus: discoid; Arthritis: juvenile idiopathic; Still's disease see Arthritis, juvenile idiopathic; Methotrexate: rheumatic disease; Sulfasalazine: rheumatic disease; Gold; Penicillamine: rheumatic disease" /><meta name="IX" content="Immunosuppressants: rheumatic disease; Gold; Penicillamine: rheumatic disease; Hydroxychloroquine; Chloroquine: rheumatic disease; Sulfasalazine: rheumatic disease; Arthritis: psoriatic; Disease-modifying antirheumatic drugs; Rheumatism, palindromic; Lupus erythematosus: systemic; Lupus erythematosus: discoid; Arthritis: juvenile idiopathic; Methotrexate: rheumatic disease; Sulfasalazine: rheumatic disease; Gold; Penicillamine: rheumatic disease" /><meta name="IXN" content="Still's disease see Arthritis, juvenile idiopathic" /><title>10.1.3 Drugs that suppress the rheumatic disease process: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP6554-drugs-that-suppress-the-rheumatic-disease-process.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP6554-drugs-that-suppress-the-rheumatic-disease-process.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP6554-drugs-that-suppress-the-rheumatic-disease-process.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP6372-musculoskeletal-and-joint-diseases.htm">10 Musculoskeletal and joint diseases</a> &gt; <a href="PHP6373-drugs-used-in-rheumatic-diseases-and-gout.htm">10.1 Drugs used in rheumatic diseases and gout</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP6539-local-corticosteroid-injections.htm" title="Previous: LOCAL CORTICOSTEROID INJECTIONS">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP6555-gold.htm" title="Next: Gold">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1><span>10.1.3 </span>Drugs that suppress the rheumatic disease process</h1><?highlighter on?><div id="pC" class="jN"><p>Certain drugs such as those affecting the immune response can suppress the disease process in <em>rheumatoid arthritis</em> and <em>psoriatic arthritis</em>; gold, penicillamine, hydroxychloroquine, chloroquine, and sulfasalazine can also suppress the disease process in <em>rheumatoid arthritis</em> while sulfasalazine and possibly gold can suppress the disease process in <em>psoriatic arthritis</em>. Unlike NSAIDs, which are used only for symptom control, disease-modifying anti-rheumatic drugs (DMARDs) can affect the progression of disease but may require 2–6 months of treatment for a full therapeutic response. Response to DMARDs may allow the NSAID dose to be reduced or withdrawn. All patients with suspected inflammatory joint disease should be referred to a specialist as soon as possible to confirm diagnosis and evaluate disease activity; early initiation of DMARDs is recommended to control the signs and symptoms, and to limit joint damage.</p> <div><h2>Choice</h2><p>The choice of a disease-modifying antirheumatic drug should take into account co-morbidity and patient preference. Methotrexate, sulfasalazine, intramuscular gold, and penicillamine are similar in efficacy. However, <strong>methotrexate</strong> or <strong>sulfasalazine</strong> may be better tolerated. </p></div> <p>A combination of <strong>DMARDs</strong> (including methotrexate and at least one other DMARD) and a short-term <strong>corticosteroid</strong> (<a title="BNF:sub-section: Corticosteroids" href="PHP6525-corticosteroids.htm">section 10.1.2</a>), should be given to patients with newly diagnosed active rheumatoid arthritis, ideally within 3 months of the onset of persistent symptoms. If the use of particular DMARDs is contra-indicated and combination therapy is not possible, monotherapy with a suitable DMARD should be given and the dose rapidly increased until clinically effective. In patients with established and stable rheumatoid arthritis, cautiously reduce drug doses to the lowest that are clinically effective. Response to drug treatment often produces a reduction in requirements of both corticosteroids and other drugs. </p> <p><strong>Gold</strong> and <strong>penicillamine</strong> are effective in <em>palindromic rheumatism</em>. <em>Systemic </em>and <em>discoid lupus erythematosus</em> are sometimes treated with <strong>chloroquine</strong> or <strong>hydroxychloroquine</strong>.</p> <p>If a disease-modifying anti-rheumatic drug does not lead to an objective benefit within 6 months, it should be replaced by a different one.</p> <div><h2>Juvenile idiopathic arthritis</h2><p>Many children with <em>juvenile idiopathic arthritis</em> (juvenile chronic arthritis) do not require disease-modifying antirheumatic drugs. Methotrexate is effective (see <a title="BNFC:monograph-family: Drugs affecting the immune response" href="http://www.medicinescomplete.com/mc/bnfc/current/PHP14378.htm"><em>BNF for Children</em></a>); sulfasalazine is an alternative [unlicensed indication] but it should be avoided in <em>systemic-onset juvenile idiopathic arthritis</em> (see <a title="BNFC:monograph-family: Sulfasalazine" href="http://www.medicinescomplete.com/mc/bnfc/current/PHP14396.htm"><em>BNF for Children</em></a>). Gold and penicillamine are no longer used. For the role of cytokine modulators in <em>polyarticular juvenile idiopathic arthritis</em>, see <a title="BNF:monograph-family: Cytokine modulators" href="PHP6607-cytokine-modulators.htm">Cytokine Modulators</a>.</p></div> </div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP6555-gold"><a href="PHP6555-gold.htm" title="Gold">Gold</a></li><li id="_PHP6565-penicillamine"><a href="PHP6565-penicillamine.htm" title="Penicillamine">Penicillamine</a></li><li id="_PHP6574-antimalarials"><a href="PHP6574-antimalarials.htm" title="Antimalarials">Antimalarials</a></li><li id="_PHP6590-drugs-affecting-the-immune-response"><a href="PHP6590-drugs-affecting-the-immune-response.htm" title="Drugs affecting the immune response">Drugs affecting the immune response</a></li><li id="_PHP6607-cytokine-modulators"><a href="PHP6607-cytokine-modulators.htm" title="Cytokine modulators">Cytokine modulators</a></li><li id="_PHP6655-sulfasalazine"><a href="PHP6655-sulfasalazine.htm" title="Sulfasalazine">Sulfasalazine</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP6539-local-corticosteroid-injections.htm">Previous: LOCAL CORTICOSTEROID INJECTIONS</a> | <a class="top" href="PHP6554-drugs-that-suppress-the-rheumatic-disease-process.htm#">Top</a> | <a accesskey="]" href="PHP6555-gold.htm">Next: Gold</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>